Introduction: The emergence of the direct oral anticoagulants (DOACs) offers patients more
convenient and accessible alternatives to warfarin or parenteral agents for the treatment of …

Abstract Objective Direct oral anticoagulants (DOACs) were developed to avoid the
limitations of vitamin K antagonists (VKAs). DOACs are associated with a greater incidence …

Abstract Aims Using Scandinavian population-based registries, we assessed risk of
stroke/systemic embolism (SE) and bleeding with non-vitamin K antagonist oral …

Atrial fibrillation (AF) accounts for 2% of the total presentations to the emergency department
(ED) and represents the most frequent arrhythmic cause for hospitalization. It steadily …

An innovative label-free electrochemical aptasensor has been developed for the precise
screening of rivaroxaban (RIV) in human blood plasma (HBP) and exhaled breath …

Background Adults with congenital heart disease (ACHD) and atrial arrhythmias (AA) face
an increased risk of thromboembolic events. Limited data exist on the use of non-vitamin K …

Aim Real-world predictors of major bleeding (MB) have been well-studied among warfarin
users, but not among all direct oral anticoagulant (DOAC) users diagnosed with atrial …

Background and purpose The early identification of cardioembolic stroke is critical for the
early initiation of anticoagulant treatment. However, it can be challenging to identify the …

Background Anti-coagulant therapy satisfaction for patients with atrial fibrillation is a critical
issue, which impacts on their treatment adherence and clinical outcomes. The …

Idarucizumab is an antibody fragment specific for the immediate reversal of dabigatran
anticoagulation effects. The use of idarucizumab is approved for dabigatran-treated patients …